← Back to Screener
Briacell Therapeutics Corp. Common Shares (BCTX)
Price$3.08
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-77.64%
Price vs S&P 500 (4W)-24.77%
VGM Score18.58
Market Capitalization$39.06M
All Metrics
Book Value / Share (Quarterly)$4.26
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.27
Price vs S&P 500 (YTD)-63.38%
EPS (TTM)$-32.56
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-32.56
EPS (Annual)$-62.19
ROI (Annual)-146.18%
Cash / Share (Quarterly)$4.12
ROA (Last FY)-119.60%
EBITD / Share (TTM)$-20.65
ROE (5Y Avg)-248.00%
Cash Flow / Share (Annual)$-14.98
P/B Ratio0.91x
P/B Ratio (Quarterly)0.88x
Net Income / Employee (Annual)$-1,315,600
Net Interest Coverage (TTM)-1.32x
ROA (TTM)-138.95%
EV / EBITDA (TTM)-1.06x
EPS Incl Extra (Annual)$-62.19
Current Ratio (Annual)5.03x
Quick Ratio (Quarterly)10.10x
3-Month Avg Trading Volume0.02M
52-Week Price Return-90.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.24
52-Week High$49.00
EPS Excl Extra (Annual)$-62.19
26-Week Price Return-69.71%
Quick Ratio (Annual)5.03x
13-Week Price Return-21.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.10x
Enterprise Value$-1.87M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.57
3-Month Return Std Dev92.73%
Net Income / Employee (TTM)$-1,481,900
ROE (Last FY)-146.18%
Net Interest Coverage (Annual)-6.72x
EPS Basic Excl Extra (Annual)$-62.19
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-32.56
Receivables Turnover (Annual)0.00x
ROI (TTM)-166.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.60
Price vs S&P 500 (52W)-114.87%
Year-to-Date Return-56.02%
5-Day Price Return-5.48%
EPS Normalized (Annual)$-62.19
ROA (5Y Avg)-72.55%
Month-to-Date Return-14.31%
EBITD / Share (Annual)$-64.08
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-200.29%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-32.56
P/TBV (Quarterly)0.88x
P/B Ratio (Annual)0.70x
Book Value / Share (Annual)$9.70
Price vs S&P 500 (13W)-29.46%
Beta1.38x
Revenue / Share (TTM)$0.00
ROE (TTM)-166.53%
52-Week Low$4.13
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXBriacell Therapeutics Corp. Common Shares | — | — | F | $3.08 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BriaCell Therapeutics is a clinical-stage biotech company developing targeted cell-based immunotherapies for cancer. Lead program Bria-IMT is in end-stage clinical trials for breast cancer, while Bria-OTS offers personalized immunotherapy options for breast and prostate cancer. The company is evaluating combination therapy approaches through clinical collaborations.